Journal of Antimicrobial Chemotherapy (1999) 43, 601-606
© 1999 The British Society for Antimicrobial Chemotherapy
Antimicrobial practice |
Early switch from intravenous to oral antibiotics: guidelines and implementation in a large teaching hospital
a Department of Internal Medicine, Division of Infectious Diseases, Tropical Medicine and AIDS b Department of Clinical Pharmacology c Hospital Pharmacy d Department of Clinical Epidemiology e Department of Medical Microbiology, Academic Medical Center, Meibergdreef 9, 1105 AZ Amsterdam, The Netherlands
Abstract
In recent years `switch therapy' has been advocated: short intravenous antibiotic therapy, for 2- 3 days, followed by oral treatment for the remainder of the course. Little is known about the number of patients that could benefit from early switch therapy and the consequences of introducing this strategy in everyday practice. We prospectively registered all antibiotic courses on wards for Internal Medicine, Surgery, and Pulmonology during a 2 month period, before (n=362, inventorial phase) and after (n=281, implementation phase) the introduction of guidelines for switching therapy. Approximately 40% of all patients who started on iv antibiotics were candidates for an early iv- oral switch. During the inventorial phase, 54% (52/97) of eligible patients were switched to oral treatment, after a median of 6 days (range 2- 28 days). After implementation of the guidelines, this percentage rose to 83% (66/80) (difference 29%, 95% CI 16- 42%; P < 0.001). Therapy was also switched earlier, after a median of 4 days (range 2 to 16 days). In the 6 weeks after completion of the oral course, recurrence of infections, or readmissions due to reinfections did not occur. Compared with the inventorial phase, 43% of iv administrations could be avoided, that is <6000 per year. This means a potential annual reduction of dfl.60,000 (c.US$30,000) of administration costs. The potential savings in purchase costs of the antibiotics were dfl.54,000 (US$27,000) annually. In conclusion, a substantial number of patients starting on iv antibiotics were candidates for an early iv- oral switch. The guidelines were well accepted by the physicians and substantial savings in costs and nursing time were achieved.
Notes
* Corresponding author. Tel:+31-205664380; Fax: +31-206972286; E-mail: j.m.prins@amc.uva.nl
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  D. Mertz, M. Koller, P. Haller, M. L. Lampert, H. Plagge, B. Hug, G. Koch, M. Battegay, U. Fluckiger, and S. Bassetti Outcomes of early switching from intravenous to oral antibiotics on medical wards J. Antimicrob. Chemother., July 1, 2009; 64(1): 188 - 199. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Colli, R. Campodonico, and T. Gherli Early Switch From Vancomycin to Oral Linezolid for Treatment of Gram-Positive Heart Valve Endocarditis Ann. Thorac. Surg., July 1, 2007; 84(1): 87 - 91. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Lee, S. K. Kim, D. Y. Lee, S. Y. Chae, and Y. Byun Pharmacokinetics of a new, orally available ceftriaxone formulation in physical complexation with a cationic analogue of bile Acid in rats. Antimicrob. Agents Chemother., May 1, 2006; 50(5): 1869 - 1871. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C.M. McLaughlin, N. Bodasing, A.C. Boyter, C. Fenelon, J.G. Fox, and R.A. Seaton Pharmacy-implemented guidelines on switching from intravenous to oral antibiotics: an intervention study QJM, October 1, 2005; 98(10): 745 - 752. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. P. J. Vogtlander, M. E. E. van Kasteren, S. Natsch, B.-J. Kullberg, Y. A. Hekster, and J. W. M. van der Meer Improving the Process of Antibiotic Therapy in Daily Practice: Interventions to Optimize Timing, Dosage Adjustment to Renal Function, and Switch Therapy Arch Intern Med, June 14, 2004; 164(11): 1206 - 1212. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. M. Prins, J. F. J. B. Nellen, R. P. Koopmans, P. N. J. Langendijk, P. M. M. Bossuyt, and P. Speelman Electronic drug ordering system can be helpful to implement iv-oral switch guidelines J. Antimicrob. Chemother., September 1, 2000; 46(3): 518 - 519. [Full Text] [PDF]
|
|